Back to top
more

Pacira BioSciences (PCRX)

(Delayed Data from NSDQ)

$30.33 USD

30.33
717,143

-0.13 (-0.43%)

Updated May 31, 2024 04:00 PM ET

After-Market: $30.34 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 401 - 420 ( 720 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 401

02/03/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 402

01/30/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 403

01/26/2017

Daily Note

Pages: 3

Just Because it Didn''t Get Bought Doesn''t Mean the DePuy Deal Isn''t a Good One

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 404

01/25/2017

Daily Note

Pages: 8

DePuy Synthes Collaboration Could Strengthen EXPAREL Sales Starting in H2:17; Reiterate OUTPERFORM and $89 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 405

01/25/2017

Company Report

Pages: 6

What Investors Are Looking for; Raising Target to $48

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 406

01/13/2017

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 407

01/10/2017

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 408

01/06/2017

Company Report

Pages: 8

Pacira Preannounced $71.4 million for Q4 Exparel Sales Compared with $70.2 million for Consensus; Reiterate OUTPERFORM and $89 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 409

01/06/2017

Daily Note

Pages: 4

Nothing But Net; Q4 Exparel Sales Surpass Guidance and Consensus

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 410

01/05/2017

Company Report

Pages: 4

Our HTX-011 Data Takeaways; Exparel Pre-Announcement Imminent

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 411

01/03/2017

Daily Note

Pages: 40

January and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 412

01/03/2017

Company Report

Pages: 18

We are initiating coverage with a Buy rating and an $43 target price

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 50.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 413

12/28/2016

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 414

12/27/2016

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 415

12/21/2016

Daily Note

Pages: 8

Symphony Health November EXPAREL Sales Estimate Accelerated Over October and Is About -3% of Consensus; Reiterate OUTPERFORM and $89 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 416

12/20/2016

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 417

12/16/2016

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 418

12/05/2016

Daily Note

Pages: 39

December and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 75.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 419

11/23/2016

Daily Note

Pages: 9

October EXPAREL and Comparators Sales Decreased Month-Over-Month; Reiterate OUTPERFORM and $89 Price Target.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 420

11/22/2016

Company Report

Pages: 7

Price: 24.95